患有肉病和COVID-19的患者的结局
Owais Nadeem1, Amreeta Sharma2, Diana Alaouie3
1a:1:{s:5:"en_US";s:19:"Henry Ford Hospital";}. onadeem1@hfhs.org.
概括
由于COVID-19而入院的类菌病患者需要更多的氧气,但死亡率较低. 免疫抑制疗法可能会降低这些患者患重症的风险.
科学领域:
- 肺部医学 肺部医学
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 2019年新冠肺炎疾病 (COVID-19) 对型硬化症患者的影响仍未得到充分研究.
- 沙丘病是一个多系统的炎症性疾病,原因不明.
研究的目的:
- 为了调查与COVID-19住院的麻症患者的结果.
- 为了识别类病患者中严重的COVID-19的危险因素.
主要方法:
- 追溯队列研究,包括被诊断患有沙尔科毒症和COVID-19的患者.
- 主要结果的分析:危急的COVID-19,需要呼吸系统支持,死亡率.
- 后勤回归用于评估关键COVID-19的风险因素.
主要成果:
- 沙丘病患者 (n=84) 需要补充氧气 (81%) 和非侵入性通风 (33.3%) 比对照组更频繁 (分别为62%和6.4%).
- 与对照组 (30.4%) 相比,撒尔科病患者的死亡率较低 (15.5%).
- 沙丘病症与严重的COVID-19没有关联,但免疫抑制疗法与风险降低相关 (OR,0.45;95%CI,0.31-0.65).
结论:
- 患有型硬化症的患者可能不会面临COVID-19严重疾病或死亡的高风险.
- 免疫抑制疗法可能会在肉病患者中提供对危急COVID-19的保护作用.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
213
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
213
01:20COPD: Pathogenesis and Clinical Features
283
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
283
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:30Pneumonia III: Complications and Assessment
237
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
237
01:28Pleural Effusion II: Symptoms and Management
181
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
181
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K